| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261
Findings from this study using a transplantable C3H mammary tumor failed to indicate interaction relative to growth parameters between two foci present in the same host. Whether they were growing alone or in the presence of a second focus, tumor growth rates were similar until the combined mass of multiple tumors approached that which was incompatible with survival. Only then was a difference in growth observed. Cytokinetic parameters, i.e., labeling index, primer-dependent DNA polymerase index or growth fraction, DNA synthesis time, tumor doubling time, and cell cycle time, were also similar whether tumors grew alone or in the presence of a second focus. Following removal of a tumor, changes were observed within 24 hr in the kinetics of the residual focus. There was an increase in labeling index (duration 
10 days) and primer-dependent DNA polymerase index with a decrease in the tumor doubling time. Minimal change was noted in DNA synthesis time and cell cycle time. The kinetic changes observed were reflected in a measurable increase in tumor size a week following tumor removal. Absence of an alteration in DNA synthesis time and cell cycle time indicates that the increase in tumor growth was probably due to a conversion of noncycling cells in Go phase into proliferation. Relationship of the findings to the use of adjuvant chemotherapy is considered.
1 Supported by USPHS Grants CA-14972 and CA-12102 and funds contributed by Luis and Antoinette Nunez of Caracas, Venezuela.
2 To whom requests for reprints should be addressed, at Department of Surgery, University of Pittsburgh School of Medicine, 914 Scaife Hall, 3550 Terrace Street, Pittsburgh, Pa. 15261.
Received 3/20/79. Accepted 6/22/79.
This article has been cited by other articles:
|
|
 |
|
  R M WYATT, B J JONES, and R G DALE Radiotherapy treatment delays and their influence on tumour control achieved by various fractionation schedules Br. J. Radiol., July 1, 2008; 81(967): 549 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Demicheli, M. W. Retsky, W. J. M. Hrushesky, M. Baum, and I. D. Gukas The effects of surgery on tumor growth: a century of investigations Ann. Onc., June 10, 2008; (2008) mdn386v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Shimizu, M. Ando, T. Kouno, N. Katsumata, and Y. Fujiwara Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer Jpn. J. Clin. Oncol., January 3, 2007; (2007) hyl122v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer Jr, E. P. Mamounas, B. Fisher, A. M. Brown, A. Robidoux, R. Margolese, M. S. Kahlenberg, et al. Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J. Clin. Oncol., May 1, 2006; 24(13): 2019 - 2027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Demicheli, R. Miceli, A. Moliterni, M. Zambetti, W. J. M. Hrushesky, M. W. Retsky, P. Valagussa, and G. Bonadonna Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process Ann. Onc., September 1, 2005; 16(9): 1449 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gadducci, E. Sartori, F. Landoni, P. Zola, T. Maggino, A. Maggioni, S. Cosio, E. Frassi, M. T. LaPresa, L. Fuso, et al. Relationship Between Time Interval From Primary Surgery to the Start of Taxane- Plus Platinum-Based Chemotherapy and Clinical Outcome of Patients With Advanced Epithelial Ovarian Cancer: Results of a Multicenter Retrospective Italian Study J. Clin. Oncol., February 1, 2005; 23(4): 751 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Love and J. E. Niederhuber Models of Breast Cancer Growth and Investigations of Adjuvant Surgical Oophorectomy Ann. Surg. Oncol., September 1, 2004; 11(9): 818 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Mano and A. Awada Primary chemotherapy for breast cancer: the evidence and the future Ann. Onc., August 1, 2004; 15(8): 1161 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Demicheli, G. Bonadonna, W. J.M. Hrushesky, M. W. Retsky, and P. Valagussa Menopausal Status Dependence of Early Mortality Reduction Due to Diagnosis of Smaller Breast Cancers (T1 v T2-T3): Relevance to Screening J. Clin. Oncol., January 1, 2004; 22(1): 102 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C.L. Schuh Trials, Tribulations, and Trends in Tumor Modeling in Mice Toxicol Pathol, January 1, 2004; 32(1_suppl): 53 - 66. [Abstract] [PDF]
|
|
|
|
|
|
C. Shannon, S. Ashley, and I.E. Smith Does Timing of Adjuvant Chemotherapy for Early Breast Cancer Influence Survival? J. Clin. Oncol., October 15, 2003; 21(20): 3792 - 3797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colleoni, G. Curigliano, I. Minchella, G. Peruzzotti, F. Nole, G. Mazzarol, G. Renne, L. Orlando, A. Rocca, P. Veronesi, et al. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase Ann. Onc., October 1, 2003; 14(10): 1477 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Mamounas NSABP Breast Cancer Clinical Trials: Recent Results and Future Directions Clin. Med. Res., October 1, 2003; 1(4): 309 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hormbrey, C. Han, A. Roberts, D. A. McGrouther, and A. L. Harris The Relationship of Human Wound Vascular Endothelial Growth Factor (VEGF) After Breast Cancer Surgery to Circulating VEGF and Angiogenesis Clin. Cancer Res., October 1, 2003; 9(12): 4332 - 4339. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kaufmann, G. von Minckwitz, R. Smith, V. Valero, L. Gianni, W. Eiermann, A. Howell, S. D. Costa, P. Beuzeboc, M. Untch, et al. International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations J. Clin. Oncol., July 1, 2003; 21(13): 2600 - 2608. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Shen, E. A. Levine, J. Hall, D. Case, G. Russell, R. Fleming, R. McQuellon, K. R. Geisinger, and B. W. Loggie Factors Predicting Survival After Intraperitoneal Hyperthermic Chemotherapy With Mitomycin C After Cytoreductive Surgery for Patients With Peritoneal Carcinomatosis Arch Surg, January 1, 2003; 138(1): 26 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Bonadonna, M. Zambetti, C. Bumma, M. Donadio, A. Bolognesi, G. Robustelli della Cuna, G. Ambrosini, G. Lelli, M. Mansutti, P. Verderio, et al. Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative Group Ann. Onc., July 1, 2002; 13(7): 1049 - 1058. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Love, N. B. Duc, N. V. Dinh, T.-Z. Shen, T. C. Havighurst, D. C. Allred, and D. L. DeMets Mastectomy and Oophorectomy by Menstrual Cycle Phase in Women With Operable Breast Cancer J Natl Cancer Inst, May 1, 2002; 94(9): 662 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Wolmark, J. Wang, E. Mamounas, J. Bryant, and B. Fisher Preoperative Chemotherapy in Patients With Operable Breast Cancer: Nine-Year Results From National Surgical Adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monographs, December 1, 2001; 2001(30): 96 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. van der Hage, C. J.H. van de Velde, J.-P. Julien, M. Tubiana-Hulin, C. Vandervelden, and L. Duchateau Preoperative Chemotherapy in Primary Operable Breast Cancer: Results From the European Organization for Research and Treatment of Cancer Trial 10902 J. Clin. Oncol., November 15, 2001; 19(22): 4224 - 4237. [Abstract] [Full Text]
|
|
|
|
|
|
M. Colleoni, S. Gelber, A. S. Coates, M. Castiglione-Gertsch, R. D. Gelber, K. Price, C.-M. Rudenstam, J. Lindtner, J. Collins, B. Thurlimann, et al. Influence of Endocrine-Related Factors on Response to Perioperative Chemotherapy for Patients With Node-Negative Breast Cancer J. Clin. Oncol., November 1, 2001; 19(21): 4141 - 4149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Roukos and A. M. Kappas Limitations in Controlling Risk for Recurrence After Curative Surgery for Advanced Gastric Cancer Are Now Well-Explained by Molecular-Based Mechanisms Ann. Surg. Oncol., September 1, 2001; 8(8): 620 - 621. [Full Text] [PDF]
|
|
|
|
|
|
A. C. Wolff and N. E. Davidson Primary Systemic Therapy in Operable Breast Cancer J. Clin. Oncol., April 7, 2000; 18(7): 1558 - 1569. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. H. M. Elkhuizen, H.-J. van Slooten, P. C. Clahsen, J. Hermans, C. J. H. van de Velde, L. C. J. M. van den Broek, and M. J. van de Vijver High Local Recurrence Risk After Breast-Conserving Therapy in Node-Negative Premenopausal Breast Cancer Patients Is Greatly Reduced by One Course of Perioperative Chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study J. Clin. Oncol., March 1, 2000; 18(5): 1075 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Colleoni, M. Bonetti, A. S. Coates, M. Castiglione-Gertsch, R. D. Gelber, K. Price, C.-M. Rudenstam, J. Lindtner, J. Collins, B. Thurlimann, et al. Early Start of Adjuvant Chemotherapy May Improve Treatment Outcome for Premenopausal Breast Cancer Patients With Tumors not Expressing Estrogen Receptors J. Clin. Oncol., February 1, 2000; 18(3): 584 - 584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. U. Buzdar, S. E. Singletary, R. L. Theriault, D. J. Booser, V. Valero, N. Ibrahim, T. L. Smith, L. Asmar, D. Frye, N. Manuel, et al. Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer J. Clin. Oncol., November 1, 1999; 17(11): 3412 - 3417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.R. Siewert, H.J. Stein, and U. Fink Multimodality Therapy for Esophageal Cancer Oncologist, August 1, 1996; 1(4): 210 - 218. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
